BioCentury
ARTICLE | Clinical News

Sanofi drops two clinical assets; reports rebounding Dupixent sales

August 3, 2018 5:12 PM UTC

Sanofi (Euronext:SAN; NYSE:SNY) disclosed in its 2Q18 earnings that it ended development of antibody-drug conjugate (ADC) SAR566658 to treat triple-negative breast cancer (TNBC), as well as a recombinant subunit vaccine to treat tuberculosis.

A Sanofi spokesperson told BioCentury that based on Phase II data, it determined SAR566658's efficacy and safety profile was not "sufficient to make a meaningful difference for patients." SAR566658 was in a registrational Phase II trial to treat TNBC. Sanofi did not respond in time for publication to inquiries regarding whether it has plans to develop the ADC for other tumor types...

BCIQ Company Profiles

ImmunoGen Inc.

Sanofi

BCIQ Target Profiles

Carbonic anhydrase IV (CAIV)